Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Cephalon Inc. Cephalon Inc. said that in a Phase I trial of its Myotrophin insulin-like growth factor-1 in 10 patients with
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury